ICU SeaStar Medical Holding Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1831868 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY145.7%
TTM net income YoY-7.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin92.6%
Operating margin-692.4%
Net margin-678.2%
FCF margin—
EBITDA margin—
Returns
ROE-246.1%
ROA-140.9%
ROIC (approx.)—
Asset turnover0.21x
Leverage & solvency
Liabilities / assets91.2%
Debt / equity0.00x
Current ratio1.03x
Interest coverage-516.93x
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-14.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.23M | $135,000 | $0 | — | — |
| Cost of revenue | $53,000 | $0 | $0 | — | — |
| Gross profit | $1.18M | $135,000 | $0 | — | — |
| R&D expense | $7.52M | $9.11M | $5.97M | $2.50M | $2.77M |
| SG&A expense | $5.84M | $8.87M | $8.24M | $6.92M | $1.68M |
| Operating income | -$12.18M | -$17.84M | -$14.21M | -$11.61M | -$4.45M |
| Interest expense | $31,000 | $244,000 | $1.08M | $630,000 | $212,000 |
| Pretax income | -$12.15M | -$24.83M | -$26.23M | -$12.19M | -$4.60M |
| Income tax | $3,000 | $3,000 | $0 | $1,000 | -$1,000 |
| Net income | -$12.15M | -$24.83M | -$26.23M | -$12.19M | -$4.60M |
| EPS (basic) | -5.86 | -66.33 | -30.26 | -1.48 | -0.63 |
| EPS (diluted) | — | -6.63 | -30.26 | -1.48 | -0.63 |
| Weighted avg. shares (diluted) | — | 3.74M | 866,813 | 8.21M | 7.24M |
| Balance sheet | |||||
| Cash & equivalents | $11.98M | $1.82M | $176,000 | $47,000 | $510,000 |
| Receivables | $237,000 | $112,000 | $0 | — | — |
| Inventory | $66,000 | $0 | — | — | — |
| Current assets | $13.58M | $3.77M | $2.31M | $1.52M | $601,000 |
| Total assets | $14.16M | $4.66M | $3.51M | $3.04M | $603,000 |
| Current liabilities | $3.74M | $6.84M | $13.05M | $16.15M | $3.12M |
| Short-term debt | — | $574,000 | $565,000 | $1.18M | — |
| Long-term debt | — | — | $4.14M | $7.65M | — |
| Total debt | — | — | $4.71M | $8.83M | — |
| Total liabilities | $3.74M | $6.84M | $17.38M | $23.80M | $3.42M |
| Shareholders' equity | $10.42M | -$2.18M | -$13.87M | -$20.76M | -$2.82M |
| Net debt | — | — | $4.53M | $8.78M | — |
| Shares outstanding | 3.84M | 650,639 | 2.02M | 12.70M | — |
| Cash flow statement | |||||
| Operating cash flow | -$13.60M | -$16.01M | -$10.29M | -$7.79M | -$5.11M |
| Investing cash flow | — | — | — | — | -$105.57M |
| Financing cash flow | $23.76M | $17.65M | $10.41M | $7.33M | $2.82M |
| Stock-based compensation | $624,000 | $887,000 | $1.93M | $1.31M | $14,000 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.